Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Our scientific activity belongs to tumor immunology: in the last fifteen years, we have contributed to the molecular definition of tumor antigens recognized by cytolytic T lymphocytes, both in human and mice, and to the validation of cancer immunotherapy in appropriate preclinical models. Here we describe two findings that we recently made in this field. The first is the discovery of a new mechanism of production of antigenic peptides, based on the splicing of peptides by the proteasome. The second is the discovery of an important mechanism of tumor resistance to immune rejection. The major interest of this mechanism is that it can be fought with pharmacological agents, which could be used to boost the efficacy of immunotherapy in cancer patients.

Type

Journal article

Journal

Bull Mem Acad R Med Belg

Publication Date

2007

Volume

162

Pages

352 - 356

Keywords

Animals, Antigens, Neoplasm, Cancer Vaccines, Clinical Trials as Topic, Disease Models, Animal, Histocompatibility Antigens, Humans, Immunotherapy, Mice, Neoplasms, Peptides, Proteasome Endopeptidase Complex, Protein Splicing, T-Lymphocytes